Global Blood Therapeutics

181 Oyster Point Blvd
South San Francisco
California
94080
United States

About Global Blood Therapeutics

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

188 articles with Global Blood Therapeutics

GBT Announces New Employment Inducement Grants - Jan 07, 2021

1/7/2021

Global Blood Therapeutics, Inc. announced that on January 1, 2021, the compensation committee of GBT’s board of directors granted six new employees restricted stock units for an aggregate of 27,500 shares of the company’s common stock.
Top 12 Biotech Companies Hiring Now

1/5/2021

The new year is here and the biotech job market is hot! A new year, a new you, a new job?
GBT Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference

1/5/2021

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual presentation at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 11:40 a.m. Eastern Time.
GBT Announces New Employment Inducement Grants - Dec 15, 2020

12/15/2020

Global Blood Therapeutics, Inc. announced that on December 1, 2020, the compensation committee of GBT’s board of directors granted eight new employees restricted stock units for an aggregate of 54,675 shares of the company’s common stock.
BioSpace Movers & Shakers, Dec. 11

12/11/2020

Biopharma and life science companies and organizations strengthen their leadership teams and boards with these Movers & Shakers.
GBT Appoints Kim Smith-Whitley, M.D., to Lead Research and Development

12/7/2020

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that world-renowned hematologist and sickle cell disease (SCD) thought leader and advocate Kim Smith-Whitley, M.D., will join the company as executive vice president and head of research and development.
GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta® (voxelotor) Tablets in Patients with Sickle Cell Disease at 62nd ASH Annual Meeting and Exposition

12/6/2020

Final 72-Week Analyses of Phase 3 HOPE Study Demonstrate Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status
GBT Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and GBT021601

12/6/2020

GBT021601 – Potent Next-Generation Hemoglobin S Polymerization Inhibitor Shown to be Highly Effective in SCD Animal Models
GBT Initiates Early Access Program for Voxelotor in Patients with Sickle Cell Disease in Europe and Other Regions Outside the United States

12/2/2020

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in Europe and other regions outside the United States, for the treatment of hemolytic anemia in sickle cell disease (SCD) patients ages 12 years and older. “With no currently approved therapies outside the United States to treat hemolytic anemia in sickle cell disease, the unmet need in this devastating di
GBT Announces Participation in Upcoming Investor Conferences - Nov 25, 2020

11/25/2020

Global Blood Therapeutics, Inc. announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences:.
GBT Announces Participation at the Stifel 2020 Virtual Healthcare Conference

11/13/2020

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, at 2:00 p.m. Eastern Time. The fireside chat will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event. About Global Blo
GBT Announces New Employment Inducement Grants - Nov 09, 2020

11/9/2020

Global Blood Therapeutics, Inc. announced that on November 1, 2020, the compensation committee of GBT’s board of directors granted 10 new employees options to purchase an aggregate of 19,500 shares of the company’s common stock with a per share exercise price of $52.88 and restricted stock units for an aggregate of 89,675 shares of the company’s common stock.
GBT Reports Recent Business Progress and Third Quarter 2020 Financial Results

11/5/2020

Achieved Oxbryta®(voxelotor)net revenues of $36.9millionwith more than 1,000new patient prescriptionsin the third quarter and net revenues of $82.5 millionthroughfirst nine months of 2020
GBT Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition

11/4/2020

Abstracts Include 72-Week Analysis of Phase 3 HOPE Study Supporting Long-Term Use of Oxbryta® (voxelotor)
GBT to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020

10/29/2020

Global Blood Therapeutics, Inc. announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020, after U.S. financial markets close.
GBT Presents Data at 15th Annual Scientific Conference on Sickle Cell and Thalassemia

10/26/2020

Real-world effectiveness data on Oxbryta® (voxelotor) in the treatment of sickle cell disease featured as oral presentation
GBT Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for Development of Oxbryta® (voxelotor) Tablets

10/12/2020

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced today it has received the 2020 Rare Impact Award®for Industry Innovation from the National Organization for Rare Disorders (NORD).
GBT Announces New Employment Inducement Grants - Oct 05, 2020

10/5/2020

Global Blood Therapeutics, Inc. announced that on October 1, 2020, the compensation committee of GBT’s board of directors granted 20 new employees options to purchase an aggregate of 12,000 shares of the company’s common stock with a per share exercise price of $57.96 and restricted stock units for an aggregate of 93,950 shares of the company’s common stock.
GBT and Sickle Cell Disease Association of America to Host 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference

9/9/2020

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Tuesday, September 15.
GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta® (voxelotor) in Six Middle Eastern Countries

9/8/2020

More than 100,000 people age 12 years and older with sickle cell disease (SCD) in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates

First
1
2
3
4
5
Next
Last